Shandong Boan Biotechnology Co., Ltd. (BOAN BIOTECH) filed its Monthly Return for Equity Issuer to the Hong Kong Stock Exchange for the month ended 31 August 2026, detailing a modest reduction in freely tradable shares following a targeted buy-back late in the month.

The company repurchased 2.00 million H-shares on 28 August 2026 at an average price of HKD 3.7355 per share, for a total outlay of approximately HKD 7.47 million. All repurchased shares have been retained as treasury stock, trimming the number of issued shares in public hands to 620.33 million from 622.33 million. The adjustment represents a 0.32% contraction in the company’s free-float while leaving the overall issued share count unchanged at 622.33 million.

Registered share capital remained steady at RMB 622.33 million, reflecting the PRC-incorporated issuer’s unchanged share-base structure. BOAN BIOTECH confirmed that it continues to meet the minimum 18.14% public-float threshold granted under its pre-listing waiver, notwithstanding the latest repurchase.

The board affirmed that all repurchase activities were executed in accordance with shareholder approval granted on 22 June 2026 and complied with Hong Kong Listing Rules and other applicable regulations. No new share options, warrants, or convertible securities were issued during the period.